Luye Pharma Group's total inventories for the quarter that ended in Dec. 2025 was €116.0 Mil. Luye Pharma Group's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was €110.6 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Luye Pharma Group's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was €-0.20.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Luye Pharma Group's Days Inventory for the
six
months ended in Dec. 2025 was 148.35.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Luye Pharma Group's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.23.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Luye Pharma Group's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.29.
Luye Pharma Group (FRA:LUP) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Luye Pharma Group's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Luye Pharma Group's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Luye Pharma Group Total Inventories Related Terms
Luye Pharma Group Total Inventories Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Luye Pharma Group (FRA:LUP) has a Total Inventories of €116.0 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Luye Pharma Group and its competitors.
Is Luye Pharma Group's Total Inventories too high?
Luye Pharma Group's current Total Inventories is €116.0 Mil. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Total Inventories compare to ZTS and UTHR?
Luye Pharma Group's Total Inventories of €116.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Luye Pharma Group and its competitors. Luye Pharma Group's current Total Inventories is €116.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Total Inventories is €116.0 Mil. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Total Inventories is €116.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Total Inventories: €116.0 Mil
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
